Loading organizations...
Loading organizations...
Origene Technologies is a technology company.
OriGene Technologies is a global gene-centric life sciences company that develops and manufactures high-quality reagents for biological research. The company specializes in producing the largest collection of full-length recombinant human proteins, covering over 50% of the human proteome. Additionally, OriGene offers highly validated antibodies, including rabbit monoclonal antibodies, for various research applications and in vitro diagnostics.
OriGene was founded in 1996 by Wei-Wu He and other experienced medical professionals. The company's initial insight centered on the critical need for a comprehensive commercial collection of full-length human cDNAs, which are essential tools for understanding gene function and protein expression. This focus established OriGene as a key provider in the genomics and proteomics space.
The company primarily serves academic researchers, biotechnology firms, and pharmaceutical companies globally, providing foundational reagents that underpin scientific discovery. OriGene's vision is to accelerate life science research by offering an expansive and high-quality portfolio of gene-centric products, thereby empowering scientists to make breakthroughs in disease understanding and therapeutic development.
Origene Technologies has raised $37.0M across 2 funding rounds.
Origene Technologies has raised $37.0M in total across 2 funding rounds.
Origene Technologies has raised $37.0M in total across 2 funding rounds.
Origene Technologies's investors include Qiming Venture Partners, KPCB China, IDG-Accel, SBI Investment, Zero2IPO, Morningside, President International Development Corporation.
OriGene Technologies is a biotechnology company founded in 1996 and headquartered in Rockville, Maryland, specializing in high-quality research tools for life sciences and clinical diagnostics.[1][2][3] It develops and commercializes products like cDNA clones, antibodies, proteins, vectors, RNAi, gene expression assay kits, and tissues, alongside services such as custom cloning, CRISPR services, antibody development, and stable cell lines.[1] Serving academic researchers, pharmaceutical companies, biotech firms, universities, research institutes, and healthcare providers worldwide, OriGene addresses challenges in basic research, drug discovery, molecular diagnostics, and personalized medicine by providing genome-wide reagents that accelerate scientific breakthroughs.[1][2][3]
With over 25 years of excellence and a portfolio exceeding 1 million research products, the company focuses on genomic and proteomic tools, including the largest commercial collection of full-length human cDNAs and over 50% coverage of the human proteome with recombinant proteins.[2][3][5] This positions OriGene as a key enabler for studying biological pathways, cancer, stem cell research, and protein kinase drug development.[3][4]
OriGene Technologies was established in 1996 as a research tool company aimed at creating the largest commercial collection of full-length human cDNAs in a standard expression vector.[1][3] Leveraging the complete human genome sequence, it evolved to develop genome-wide tools for system biology approaches, enabling drug target identification and deeper insights into disease mechanisms like cancer and stem cell research.[3] Early milestones include releasing 22,000 unique full-length genes, sequencing 800,000 clones from primary cDNA libraries, and shuttling over 15,000 ORF cDNAs into proprietary eukaryotic expression systems to produce 12,000 validated human proteins in HEK293T cells.[4]
The company has grown into a global gene-centric biotech leader, securing SBIR grants for innovations like high-throughput mouse cDNA cloning ($139,970) and protein microarray technology ($256,200) for proteomic research.[4] This trajectory reflects a commitment to pioneering reagents that support siRNA libraries, protein production, and advanced research platforms.[2][4]
OriGene rides the wave of genomic and proteomic advancements, capitalizing on post-human genome sequencing to fuel system biology, drug discovery, and personalized medicine.[3] Its timing aligns with rising demands for high-throughput tools in cancer, stem cell, and protein kinase research, where comprehensive reagents are essential for target validation and pathway analysis.[3][4] Market forces like expanding biotech R&D, growth in molecular diagnostics, and needs from pharma/biotech (e.g., antibody testing, custom proteins) favor OriGene's U.S.-based, scalable production.[1]
By providing critical reagents to academia, industry, and clinics worldwide, OriGene influences the ecosystem through SBIR-funded innovations and tools that accelerate breakthroughs, reducing barriers in proteomics and enabling faster translation from research to diagnostics.[2][4][5]
OriGene is poised to expand its dominance in proteomic tools amid surging AI-driven drug discovery and precision medicine trends, potentially deepening proteome coverage and integrating CRISPR/AAV services for next-gen therapies.[1][2] Evolving regulations in IVD and global R&D investments will shape its path, with opportunities in high-throughput microarrays and custom reagents for emerging diseases.[4] Its influence may grow by powering more collaborative ecosystems, solidifying its role as a foundational biotech enabler much like its early cDNA collections transformed genomics.
Origene Technologies has raised $37.0M across 2 funding rounds. Most recently, it raised $21.0M Series C in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $21.0M Series C | Qiming Venture Partners, KPCB China | IDG-Accel |
| Mar 17, 2010 | $16.0M Series B | IDG-Accel, SBI Investment, Zero2IPO | Morningside, President International Development Corporation |